InterStim Therapy System, Verify Evaluation System
Medtronic Neuromodulation · Decision date Oct 6, 2026
What did the FDA approve?
FDA recorded an approval decision dated 2026-10-06 for PMA supplement P970004/S457, submitted by Medtronic Neuromodulation under the InterStim™ Therapy System, Verify™ Evaluation System title. The supplement is classified as a Real-Time Process submission with the stated reason Change Design/Components/Specifications/Material, and the recorded statement describes a new stand-alone torque wrench kit configuration (Model B31020-T).
The decision applies to that supplement within the existing P970004 approval rather than constituting a new approval of the whole system. The device category is listed as Stimulator, electrical, implantable, for incontinence, with Gastroenterology and Urology specialties and product code EZW. The source record does not include the supplement documents, so the technical basis for the change and any conditions of approval remain unknown from this data alone.
FDA approval order statement
a new stand-alone torque wrench kit configuration (Model B31020-T)
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Oct 6, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P970004/S457
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic Neuromodulation
- Product code
- EZW
- Decision code
- APPR
- Decision date
- Oct 6, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, electrical, implantable, for incontinence.
- Applicant
- Medtronic Neuromodulation
- Product code
- EZW
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P970004. Subsequent supplements may change the device or its indications.
FDA decision timeline
P970004 · Original PMA
MEDTRONIC INTERSTIM THERAPY SYSTEM FOR URINARY CONTROL
P970004/S457 received
Application receipt date recorded by FDA.
P970004/S458 · Related supplement
InterStim Therapy System Verify Evaluation System
P970004/S457 · FDA decision
Real-Time Process
P970004/S459 · Related supplement
InterStim Therapy System, Verify Evaluation System
P970004/S460 · Related supplement
InterStim Therapy System, Verify Evaluation System (SNS Urinary Neurostimulator 97800), (SNS Urinary Neurostimulator I
Timeline entries are records held by MedtechLedger for P970004. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P970004
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Neuromodulation | PMA approval | Sep 29, 1997 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Sep 14, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 9, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 29, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Neuromodulation
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 7000 Central Ave., NE, Minneapolis, MN, 55432
Sources and methodology
- Original FDA record: P970004/S457
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

